Zhitong Finance App News, Baiyang Pharmaceutical (301015.SZ) announced that the company and AstraZeneca Business Consulting (Wuxi) Co., Ltd., CICC Capital Operation Co., Ltd., Shandong New Kinetic Energy Fund Management Co., Ltd., Qingdao Innovation Investment Co., Ltd., Qingdao Guidance Fund Investment Co., Ltd., Qingdao Hi-Tech Industry Development Parent Fund Partnership (Limited Partnership), Wuxi AstraZeneca CICC Venture Capital Partnership (Limited Partnership), Jinan Hi-Tech Finance Investment Co., Ltd., Yinfeng Finance (Beijing) Investment Management Co., Ltd., Tianjin Jiashan Industrial Development Investment Co., Ltd. Funded the establishment of AstraZeneca CICC Qingdao Healthcare Venture Capital Fund (limited partnership) (tentative name). The total amount of pledged capital of the partnership was 1 billion yuan. As a limited partner, the company pledged 50 million yuan with its own funds, accounting for 5% of the total pledged capital.

The partnership will focus on investment projects in the healthcare sector (including but not limited to biomedicine and biotechnology) in China, giving priority to supporting projects determined by the Shandong Provincial Committee and Provincial Government and major project bank projects for the conversion of old and new kinetic energy in Shandong Province.

According to the announcement, the company can improve the company's overall strategic layout through investment fund layout in areas that are relevant and synergetic to the company's main business, further promote the company's development, enhance the company's overall competitiveness and core competitiveness, and enhance the company's sustainable development capabilities.